Wockhardt Ltd.

NSE: WOCKPHARMA BSE: 532300 SECTOR: Pharmaceuticals & Drugs

431.3
-8.9 (-2.02%)
NSE: 20 Sep 04:12 PM

Price Summary

Today's High

₹ 452

Today's Low

₹ 426.4

52 Week High

₹ 804.9

52 Week Low

₹ 266

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.

Company Essentials

Market Cap

4779.01 Cr.

Enterprise Value

6253.57 Cr.

No. of Shares

11.08 Cr.

P/E

0

P/B

3.12

Face Value

₹ 5

Div. Yield

0%

Book Value (TTM)

₹  138.04

CASH

138.4 Cr.

DEBT

1612.96 Cr.

Promoter Holding

69.68%

EPS (TTM)

₹  -20.02

Sales Growth

-24.08%

ROE

46.66 %

ROCE

34.84 %

Profit Growth

356.7 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Ratios

Sales Growth

1 Year-24.08%
3 Year-25.1%
5 Year-14.03%

Profit Growth

1 Year356.7%
3 Year105.2%
5 Year134.65%

ROE%

1 Year46.66%
3 Year6.19%
5 Year7.2%

ROCE %

1 Year34.84%
3 Year10.25%
5 Year9.63%

Debt/Equity

1.022

Price to Cash Flow

-8.47

Interest Cover Ratio

5.29694366759888

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2021 69.68 34.44
Mar 2021 72.12 18.71
Dec 2020 72.12 10.14
Sep 2020 72.12 22.41
Jun 2020 72.13 26.42
* Figures given above are % of equity capital

 Strengths

  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 11.7313213566423.

 Limitations

  • The company has shown a poor revenue growth of -25.0983657824155% for the Past 3 years.
  • Company has a poor ROE of 6.1914320421731% over the past 3 years.
  • Company has high debtor days of 332.116690682037.
  • Company has negative cash flow from operations of -563.97.
  • The company has a low EBITDA margin of 2.24337123316488% over the past 5 years.
  • The company is trading at a high EV/EBITDA of 682.0804.
  • Promoter pledging is high as 34.44%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
Net Sales 177.58 294.96 252.97 261.75 278.95
Total Expenditure 273.13 307.27 261.03 285.48 274.24
Operating Profit -95.55 -12.31 -8.06 -23.73 4.71
Other Income 9.74 14.96 9.72 8.26 15.62
Interest 58.61 46.97 49.2 45.46 55.43
Depreciation 46.08 42.97 42.72 52.31 42.47
Exceptional Items -142.48 0 0 0 0
Profit Before Tax -332.98 -87.29 -90.26 -113.24 -77.57
Tax -114.04 -29.91 -21.59 -66.19 -28.88
Profit After Tax -218.94 -57.38 -68.67 -47.05 -48.69
Adjusted EPS (Rs) -19.77 -5.18 -6.2 -4.25 -4.4

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Net Sales 2297.52 2477.29 2149.95 1371.22 1041
Total Expenditure 2164.07 2154.4 2069.48 1401.8 1136.13
Operating Profit 133.45 322.89 80.47 -30.58 -95.13
Other Income 259.71 56.85 34.8 85.82 12.03
Interest 168.72 169.58 170.88 220.17 200.24
Depreciation 105.66 106.24 119.82 173.39 184.08
Exceptional Items 0 0 0 0 1327.84
Profit Before Tax 118.78 103.92 -175.43 -338.32 860.42
Tax -18.34 35.26 -93.54 -107.2 267.13
Net Profit 137.12 68.66 -81.89 -231.12 593.29
Adjusted EPS (Rs.) 12.4 6.21 -7.4 -20.87 53.56

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Equity and Liabilities
Share Capital 55.27 55.32 55.34 55.37 55.39
Total Reserves 1164.05 1239.37 1171.29 939.25 1550.37
Borrowings 1282.62 758.39 941.93 519.5 259.45
Other N/C liabilities 414.78 499.5 402.98 692.74 271.79
Current liabilities 1594.02 1789.03 1827.74 2305.25 2602.79
Total Liabilities 4510.74 4341.61 4399.28 4512.11 4739.79
Assets
Net Block 1464.51 1422.73 1614.32 2044.35 1683.66
Capital WIP 665.34 653.34 380.9 305.29 306.5
Intangible WIP 0 0 0 0 409.2
Investments 297.22 297.22 297.27 297.27 297.27
Loans & Advances 276.25 276.39 236.22 202.02 203.35
Other N/C Assets 10.65 24.81 40.63 56.63 0.84
Current Assets 1796.77 1667.12 1829.94 1606.55 1838.97
Total Assets 4510.74 4341.61 4399.28 4512.11 4739.79
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Profit from operations 118.78 103.92 -175.43 -338.32 860.42
Adjustment 35.72 251.33 273.57 355.96 -994.97
Changes in Assets & Liabilities -364.51 -225.82 -15.4 204.37 -318.14
Tax Paid -25.01 -10.05 -24.41 -0.5 -111.28
Operating Cash Flow -235.02 119.38 58.33 221.51 -563.97
Investing Cash Flow 368.83 450.73 120.33 -16.15 1014.34
Financing Cash Flow -133.06 -523.84 -69.42 -273.97 -479.85
Net Cash Flow 0.75 46.27 109.24 -68.61 -29.48

Corporate Actions

Investors Details

PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
Promoters 72.13 72.12 72.12 72.12 69.68
ananke trustee company pr... 4.22 4.22 4.22 4.22 3.77
callirhoe trustee company... 4.08 4.08 4.08 4.08 3.54
habil f khorakiwala 0.4 0.4 0.41 0.41 0.41
huzaifa habil khorakiwala... 0.2 0.2 0.19 0.19 0.19
murtaza habil khorakiwala... 0.2 0.2 0.2 0.2 0.2
pasithee trustee company ... 4.42 4.42 4.42 4.42 3.97
themisto trustee company ... 58.6 58.59 58.58 58.58 57.59
habil f khorakiwala 0.4 0.4 0.41 0.41 0.41
PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
Public 22.97 23.19 23.75 24.69 27.49
hardik b. patel 0 0 0 0 0
iepf 0.08 0.09 0.15 0.16 0.18
jhunjhunwala rakesh radhe... 0 0 2.26 2.26 2.26
PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
FII/DII 4.9 4.69 4.12 3.19 2.82
delaware group global and... 1.08 1.08 0 0 0
delaware group global and... 1.08 1.08 0 0 0

Company Presentations

Company News

Wockhardt informs about press release26 Aug 2021, 9:43AM Wockhardt’s arm enters into partnership with Jemincare26 Aug 2021, 9:32AM Wockhardt partners with RDIF13 Aug 2021, 1:54PM Wockhardt informs about press release27 Jul 2021, 4:15PM Wockhardt reports consolidated net loss of Rs 13 crore in Q122 Jul 2021, 2:33PM Wockhardt incorporates new subsidiary5 Jul 2021, 10:02AM Wockhardt informs about disclosure2 Jul 2021, 9:52AM Wockhardt informs about disclosure23 Jun 2021, 9:58AM Wockhardt informs about revised disclosure3 Jun 2021, 2:26PM Wockhardt informs about allotment of NCDs on private placement basis29 May 2021, 11:41AM Wockhard informs about disclosure29 May 2021, 9:52AM Wockhardt informs about disclosure24 May 2021, 4:28PM Wockhardt gets nod to raise Rs 150 crore 22 May 2021, 11:56AM Wockhardt informs about compliance report20 May 2021, 3:07PM Wockhardt informs about disclosure19 May 2021, 9:49AM Wockhardt gets approval to raise funds upto Rs 150 crore22 Apr 2021, 10:16AM Wockhardt planning to raise funds through NCDs19 Apr 2021, 11:23AM Wockhardt awarded six-month extension of agreement with UK Govt to fill-finish COVID-19 vaccines10 Feb 2021, 1:14PM Wockhardt informs about disclosure1 Dec 2020, 10:21AM Wockhardt turns black in Q22 Nov 2020, 4:46PM Wockhardt informs about newspaper publication25 Sep 2020, 10:38AM Wockhardt turns black in Q131 Aug 2020, 3:54PM Wockhardt - Quaterly Results29 Aug 2020, 12:56PM Wockhardt - Quaterly Results29 Aug 2020, 12:56PM Wockhardt informs about press release3 Aug 2020, 3:24PM Wockhardt enters into partnership with UK Government3 Aug 2020, 2:44PM Wockhardt gets nod to raise fund up to Rs 1,500 crore12 May 2020, 2:24PM Wockhardt gets QIDP designation from USFDA for its combination antibiotic21 Apr 2020, 12:21PM

Wockhardt Stock Price Analysis and Quick Research Report. Is Wockhardt an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Wockhardt and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs -563.97 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Wockhardt has a Debt to Equity ratio of 1.022 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Wockhardt , the EPS growth was 356.609457085542 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Wockhardt has OPM of -9.13832853025938 % which is a bad sign for profitability.
     
  • ROE: Wockhardt have a healthy ROE of 46.6626554825415 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Wockhardt

X